[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334451-105":59,"doc-detail-334451-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genotype-phenotype-correlations-in-carriers-of-the-pms2-founder-variant-c1831dup","Genotype–phenotype correlations in carriers of the PMS2 founder variant c.1831dup","","Background: Lynch syndrome is a common hereditary cancer predisposition caused by germline pathogenic variants in DNA mismatch repair genes. A recurrent PMS2 pathogenic variant, c.1831dup, accounts for 27% of Swiss PMS2 index patients and includes early-onset colorectal cancer cases. Methods: The study tested whether c.1831dup represents a founder variant via haplotype analysis and whether it links to a more severe clinical phenotype. Results: Haplotype sharing was observed in 81% of index patients, and combined analyses suggested earlier age at colorectal diagnosis plus atypical MMR protein patterns. Conclusion: The findings support an ancient founder mutation and potential association with earlier CRC onset.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genotype-phenotype-correlations-in-carriers-of-the-pms2-founder-variant-c1831dup/334451/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genotype-phenotype-correlations-in-carriers-of-the-pms2-founder-variant-c1831dup/334451.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main focus of the study on PMS2 c.1831dup carriers?","Question",{"text":112,"@type":113},"The study evaluated whether the PMS2 pathogenic variant c.1831dup represents a founder variant using haplotype analysis and whether it correlates with a more severe clinical phenotype.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did haplotype analysis show for c.1831dup index patients?",{"text":117,"@type":113},"It identified a shared common region of about 0.7 Mb/1.3 cM in 13 (81%) out of 16 index patients, supporting a founder effect.",{"name":119,"@type":110,"acceptedAnswer":120},"How did c.1831dup carriers differ clinically from carriers of other PMS2 pathogenic variants?",{"text":121,"@type":113},"Genotype–phenotype correlations indicated earlier age at colorectal cancer diagnosis in c.1831dup carriers (55% vs. 29%; p = 0.047) and showed that 30% of cancers had atypical MMR protein expression patterns on immunohistochemistry.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334451,1790845659,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","DOI: 10.1002/mgg3.2360  \nORIGINAL ARTICLE  \nGenotype–phenotype correlations in carriers of thePMS2 founder variant c.1831dup  \nMelanie Gass1 | Britta Seebauer1 | Aline Thommen1 | Alexandra Fischler1 | Karl Heinimann1,2  \n1Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland  \n2Research Group Human Genomics, Department of Biomedicine, University of Basel, Basel, Switzerland  \nCorrespondence  \nKarl Heinimann, Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. [Email:](Email: karl.heinimann@usb.ch)[ karl.heinimann@usb.ch](Email: karl.heinimann@usb.ch)  \nPresent address  \nBritta Seebauer, Genetica AG, Zurich, Switzerland  \n1 | INTRODUCTION  \nAbstract  \nBackground: Lynch syndrome represents one of the most common cancer predispositions worldwide and is caused by germline pathogenic variants (PV) in DNA mismatch repair (MMR) genes. We repeatedly identified a PV in the MMR gene PMS2, c.1831dup, accounting for 27% of all Swiss PMS2 PV index patients identified. Notably, 2/18 index patients had been diagnosed with colorectal cancer (CRC) before age 30.  \nMethods: In this study, we investigated if this PV could (i) represent a founder variant by haplotype analysis and (ii) be associated with a more severe clinical phenotype.  \nResults: Haplotype analysis identified a shared common region of about 0.7 Mb/1.3 cM in 13 (81%) out of 16 index patients. Genotype–phenotype correlations, combining data from the 18 Swiss and 18 literature-derived PMS2 c.1831dup PV index patients and comparing them to 43 Swiss index patients carrying other PMS2 PVs, indicate that the PMS2 c.1831dup variant may be associated with earlier (\u003C50 y) age at CRC diagnosis (55% vs. 29%, respectively; p = 0.047) . Notably, 30%(9/30) of cancers from c.1831dup carriers displayed atypical MMR protein expression patterns on immunohistochemistry.  \nConclusion: Our results suggest that thePMS2 c.1831dup PV represents a, probably ancient, founder mutation and is possibly associated with an earlier CRC diagnosis compared to other PMS2 PVs.  \nKEYWORDS  \nhaplotype, Lynch syndrome, PMS2 founder variant, PMS2 variants, PMS2-associated Lynch syndrome  \nestimated 1 in 279 individuals (Dominguez-Valentinet al., 2020; Win et al., 2017). It is caused by heterozygous  \nLynch syndrome (LS) represents one of the most common cancer predispositions known today, affecting an  \ngermline pathogenic variants (PV) in one of the four DNA mismatch repair (MMR) genes: MLH1 (OMIM: *120436),  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.  \nMol Genet Genomic Med. 2024;12:e2360 .  \n[https://doi.org/10.1002/mgg3.2360](https://doi.org/10.1002/mgg3.2360)  \n[wileyonlinelibrary.com/journal/mgg3](wileyonlinelibrary.com/journal/mgg3)  \n1 of 10  \nMSH2 (OMIM: *609309), MSH6 (OMIM: *600678), and PMS2 (OMIM: *600259) . Patients have a significantly increased, gene-specific lifetime risk for several cancer types, predominantly colorectal (up to 57%) and endometrial cancer (up to 48%) and, more rarely (about 1% to 17%), other tumors like ovarian, gastric, small bowel, and urinary tract cancer (Dominguez-Valentin et al., 2020; Lynch et al., 2015) . Several studies have shown that MSH6-and PMS2-associated LS display an attenuated phenotype with lower lifetime risks and a later age of first cancer diagnosis compared to MLH1- and MSH2-associated LS, resulting in gene-specific adaptations of surveillance recommendations (Bonadona et al., 2011; Broeke et al., 2018; Dominguez-Valentin et al., 2020; Jenkins et al., 2021; Seppälä et al., 2021; Ten Broeke et al., 2015) . Thus, while regular colonoscopies for patients wit","cbCaik3YJNJOsuJL","https://ap.wps.com/l/cbCaik3YJNJOsuJL","pdf",573343,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Lynch syndrome overview\n## Surveillance and therapeutic implications\n# PMS2 variant prevalence and founder mutations","[{\"question\":\"What was the main focus of the study on PMS2 c.1831dup carriers?\",\"answer\":\"The study evaluated whether the PMS2 pathogenic variant c.1831dup represents a founder variant using haplotype analysis and whether it correlates with a more severe clinical phenotype.\"},{\"question\":\"What did haplotype analysis show for c.1831dup index patients?\",\"answer\":\"It identified a shared common region of about 0.7 Mb/1.3 cM in 13 (81%) out of 16 index patients, supporting a founder effect.\"},{\"question\":\"How did c.1831dup carriers differ clinically from carriers of other PMS2 pathogenic variants?\",\"answer\":\"Genotype–phenotype correlations indicated earlier age at colorectal cancer diagnosis in c.1831dup carriers (55% vs. 29%; p = 0.047) and showed that 30% of cancers had atypical MMR protein expression patterns on immunohistochemistry.\"}]","Genotype–phenotype correlations in carriers of the PMS2 founder variant c.1831dup | PDF",1790006722,25]